8V6 Stock Chart & Stats
€0.39
>-€0.01(-6.14%)
At close: 4:00 PM EST
€0.39
>-€0.01(-6.14%)
Day’s Range― - ―
52-Week Range€0.13 - €0.68
Previous CloseN/A
Volume0.00
Average Volume (3M)7.00
Market Cap
€7.44M
Enterprise Value€92.22
Total Cash (Recent Filing)€1.46M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta-0.98
Next Earnings
Aug 11, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.25
Shares Outstanding23,802,313
10 Day Avg. Volume0
30 Day Avg. Volume7
Financial Highlights & Ratios
PEG Ratio0.35
Price to Book (P/B)37.86
Price to Sales (P/S)9.82
P/FCF Ratio-28.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)€1.72M
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthSustained ~265% TTM revenue growth signals tangible commercial traction for the IQWave/TSE platform and expanding market adoption. Over a 2–6 month horizon, continued top-line expansion should build recurring consumable and service revenue, enabling scale and improving the path to cover fixed operating costs if growth persists.
Positive Gross Margin RecoveryA move to ~53% gross margin demonstrates the product and consumable unit economics are now profitable at the point of sale. Durable gross profitability supports operating leverage as revenue scales, making long-term profitability achievable if SG&A growth is controlled and installed-base driven consumable sales increase.
No Financial LeverageZero net debt materially lowers interest and refinancing risk, giving the company flexibility to prioritize commercialization and R&D without fixed finance costs. This structural strength lengthens runway relative to highly levered peers and improves optionality for non-dilutive funding or strategic partnerships over the medium term.
Bears Say
Persistent Net LossesA ~-50% net margin indicates operating costs far exceed gross profit, meaning headline profitability is distant despite revenue gains. Persistent losses erode capital and require recurring external funding; unless operating expenses are reined in or revenue accelerates materially, sustained losses will hinder durable financial stability and long-term investor returns.
Negative Operating And Free Cash FlowConsistent negative operating and free cash flow means the business consumes cash to run and grow. Even with improved burn versus earlier years, TTM FCF deterioration versus 2025 raises funding risk. Over months, this limits the firm's ability to self-fund commercial expansion and may force dilutive financing or constrained investments.
Eroding Equity BaseA materially reduced equity base reflects cumulative losses and weak capital retention, shrinking the financial cushion for setbacks. Negative ROE signals inability to generate returns on invested capital, increasing dependency on external capital and raising dilution risk, which can undermine long-term shareholder value and strategic flexibility.
Scandinavian ChemoTech AB Class B News
8V6 FAQ
What was Scandinavian ChemoTech AB Class B’s price range in the past 12 months?
Scandinavian ChemoTech AB Class B lowest stock price was €0.13 and its highest was €0.68 in the past 12 months.
What is Scandinavian ChemoTech AB Class B’s market cap?
Scandinavian ChemoTech AB Class B’s market cap is €7.44M.
When is Scandinavian ChemoTech AB Class B’s upcoming earnings report date?
Scandinavian ChemoTech AB Class B’s upcoming earnings report date is Aug 11, 2026 which is in 9 days.
How were Scandinavian ChemoTech AB Class B’s earnings last quarter?
Scandinavian ChemoTech AB Class B released its earnings results on May 20, 2026. The company reported -€0.006 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Scandinavian ChemoTech AB Class B overvalued?
According to Wall Street analysts Scandinavian ChemoTech AB Class B’s price is currently Overvalued.
Does Scandinavian ChemoTech AB Class B pay dividends?
Scandinavian ChemoTech AB Class B does not currently pay dividends.
What is Scandinavian ChemoTech AB Class B’s EPS estimate?
Scandinavian ChemoTech AB Class B’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Scandinavian ChemoTech AB Class B have?
Scandinavian ChemoTech AB Class B has 23,802,313 shares outstanding.
What happened to Scandinavian ChemoTech AB Class B’s price movement after its last earnings report?
Scandinavian ChemoTech AB Class B reported an EPS of -€0.006 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.473%.
Which hedge fund is a major shareholder of Scandinavian ChemoTech AB Class B?
Currently, no hedge funds are holding shares in DE:8V6
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Scandinavian ChemoTech AB Class B
Scandinavian ChemoTech AB (publ), a medical technology company, engages in the radiation physics, surgical oncology, and clinical development in Sweden and internationally. It operates in two divisions, Human Care and Animal Care. The company offers IQWave, an electroporation that generates a tumour-specific electrical stimulation; and veterinary medicines under the vetIQur name. Scandinavian ChemoTech AB (publ) was incorporated in 2013 and is headquartered in Lund, Sweden.
Technical Analysis
2cureX AB
―
OncoZenge AB
―
ExpreS2ion Biotech Holding AB
―
CombiGene AB
―
Sprint Bioscience AB
―